Axovant Sciences Ltd (NASDAQ:AXON) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 4,188,830 shares, a growth of 39.1% from the January 15th total of 3,010,613 shares. Currently, 8.0% of the shares of the company are short sold. Based on an average trading volume of 1,081,989 shares, the days-to-cover ratio is presently 3.9 days.
In other Axovant Sciences news, major shareholder Svf Investments (Uk) Ltd purchased 10,000,000 shares of the company’s stock in a transaction dated Tuesday, December 18th. The shares were acquired at an average price of $1.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the insider now directly owns 99,285,714 shares of the company’s stock, valued at approximately $99,285,714. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in AXON. Monashee Investment Management LLC bought a new stake in shares of Axovant Sciences during the 4th quarter valued at $996,000. Renaissance Technologies LLC raised its position in shares of Axovant Sciences by 60.5% during the 3rd quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock valued at $5,062,000 after purchasing an additional 788,100 shares during the period. Hudson Bay Capital Management LP raised its position in shares of Axovant Sciences by 23.8% during the 4th quarter. Hudson Bay Capital Management LP now owns 1,250,000 shares of the biotechnology company’s stock valued at $1,245,000 after purchasing an additional 240,000 shares during the period. BlackRock Inc. raised its position in shares of Axovant Sciences by 13.5% during the 3rd quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock valued at $3,447,000 after purchasing an additional 169,918 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Axovant Sciences by 12.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock valued at $1,354,000 after purchasing an additional 64,152 shares during the period. Hedge funds and other institutional investors own 7.58% of the company’s stock.
Shares of AXON stock opened at $1.22 on Thursday. The firm has a market cap of $157.74 million, a PE ratio of -0.59 and a beta of 1.21. Axovant Sciences has a one year low of $0.93 and a one year high of $6.59. The company has a debt-to-equity ratio of 1.24, a quick ratio of 2.02 and a current ratio of 2.02.
Axovant Sciences (NASDAQ:AXON) last announced its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.27) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.27). On average, equities analysts forecast that Axovant Sciences will post -1.25 EPS for the current fiscal year.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Featured Article: QQQ ETF
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.